Scientists from the CU Anschutz School of Medicine have identified a new method to treat alcohol use disorder (AUD), using a drug that boosts dopamine in the prefrontal cortex, potentially offering a novel approach to managing the condition. The University NetworkIn a groundbreaking study, researchers at the University of Colorado Anschutz School of Medicine have identified a new approach to treating alcohol use disorder (AUD). Currently, AUD treatments function primarily in two ways: by reducing the euphoria associated with alcohol consumption or by lessening the cravings for alcohol. Focus on the Prefrontal Cortex“The current medications for AUD target the neurotransmitter dopamine in the reward-related parts of the brain,” Schacht added. They turned to tolcapone, an FDA-approved drug initially designed for Parkinson’s disease, which increases dopamine levels in the prefrontal cortex.